CF
Health Outcomes Differ Between U.K. and U.S. Children With Cystic Fibrosis
The researchers compared the longitudinal trajectories of lung function in 9,463 children from the United States ...
MAY 14, 2021
The Role of the Specialty Pharmacist in Treating Cystic Fibrosis
Cystic fibrosis—once considered a disease destined to result in childhood mortality—has seen median age ...
FEBRUARY 19, 2021
New CF Drug’s Success a Matter of Timing
Onboarding with elexacaftor-tezacaftor-ivacaftor (Trikafta, Vertex) is keeping clinical pharmacists across the ...
FEBRUARY 26, 2020
FDA Approves Trikafta for Cystic Fibrosis
he presence of at least one F508del mutation should be confirmed using an FDA-cleared genotyping assay before ...
OCTOBER 21, 2019
CMV Linked to Faster Progression in CF
Signs of faster progression in cystic fibrosis patients included earlier times to lung transplant referral and ...
APRIL 8, 2019
Efficacy of Antibiotics in CF Patients May Be Affected by pH, Oxygen in Lungs
Changing the pH environment in the lungs might help CF patients battle chronic lung infections.
OCTOBER 19, 2018
FDA Approves Symdeko for CF Patients
Symdeko by Vertex is indicated for people with two copies of the F508del mutation in the CFTR gene or who have at ...
FEBRUARY 13, 2018
FDA Expands Indication for Kalydeco in CF
This new indication enables 900 more CF patients to use this medication.
MAY 19, 2017